Successful Tepotinib Rechallenge after Tepotinib-induced Adverse Events Following Pembrolizumab Failure in a Case of Non-small Cell Lung Carcinoma with MET Exon 14 Skipping.

Abstract excerpt

We herein report a case of successful rechallenge with tepotinib after tepotinib-induced adverse events following first-line treatment failure with pembrolizumab in a patient with non-small cell lung carcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutations. Initial tepotinib administration was suspended because of hepatotoxicity and hypersensitivity. However, the re-administration...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies, Monoclonal, Humanized
• Share to Antineoplastic Agents, Immunological